Effects of omega-3 fatty acid nutrition on mortality in septic patients: a meta-analysis of randomized controlled trials

Wei Tao, Ping-Song Li, Zhou Shen, Yu-Sheng Shu and Sen Liu

Abstract

Background: A previous systematic review and meta-analysis reported that omega-3 fatty acids nutrition may reduce mortality in septic patients. As new randomized controlled trials began to accumulate, we conducted an update.

Methods: A PubMed database was searched through Feb 2016, and randomized controlled trials comparing omega-3 fatty acids with control were selected by two reviewers independently.

Results: Eleven trials randomly assigning 808 patients were included in the present study. Using a fixed effects model, we found no significant effect of omega-3 fatty acids on overall mortality (risk ratio 0.84; 95 % confidence interval (CI): 0.67 to 1.05, \( P = 0.12 \)), or infectious complications (risk ratio 0.95; 95 % CI: 0.72 to 1.25, \( P = 0.70 \)). However, the duration of mechanical ventilation was markedly reduced by omega-3 fatty acids (weighted mean differences (WMD) = −3.82; 95 % CI: −4.61 to −3.04; \( P < 0.00001 \)). A significant heterogeneity was found when the duration of hospital (\( I^2 = 93 \% \); WMD = −2.82; 95 % CI: −9.88 to 4.23, \( P = 0.43 \)) or intensive care stay (\( I^2 = 87 \% \); WMD = −2.70; 95 % CI: −6.40 to 1.00, \( P = 0.15 \)) were investigated.

Conclusions: Omega-3 fatty acids confer no mortality benefit but are associated with a reduction in mechanical ventilation duration in septic patients. However, low sample size and heterogeneity of the cohorts included in this analysis limits the generalizability of our findings.

Keywords: Omega-3 fatty acids, Sepsis, Mortality

Background

Sepsis is a life threatening systemic inflammatory syndrome that is triggered by infection, and it is a major cause of death in critical ill patients such as severe burn [1, 2]. Even with dramatic advances in pharmacology as well as the technology of intensive care and life supporting, the mortality estimates in septic patients is as high as over 25 % [1]. It is suggested that when complicated with organ failure or shock, the mortality in septic patients could be further elevated to 33.2 % [3–5]. Thus, strategies that could play a benefit on survival in septic patients are appreciated.

Omega-3 fatty acids are reported to have a protective role in cardiovascular diseases [6]. And it is also recognized that omega-3 fatty acids have anti-inflammatory and immunomodulating features [7]. Recently, a number of studies have focused on the effect of omega-3 fatty acids on septic patients [8–17]. However, inconsistent findings were reported between trials. A systematic review and meta-analysis published in 2014 found mortality in septic patients could be reduced by parenteral nutrition of omega-3 fatty acids [18]. However, as the low quality of enrolled trials, the authors concluded that the effect of omega-3 fatty acids on the mortality of sepsis was uncertain [18]. Meanwhile, as new randomized controlled trials began to accumulate, we conducted an update and in the present meta-analysis, our goal was to evaluate the effect of omega-3 fatty acids nutrition on mortality, the duration of hospital, intensive care unit...
(ICU) stay, infectious complications, and the duration of mechanical ventilation in septic patients.

**Methods**

**Search strategy**
The present study was conducted according to the Preferred Reporting Items for Systematic reviews and Meta Analysis (PRISMA) of randomized controlled trials [19]. We conducted an electronic search of PubMed database up to Feb 2016 for relevant studies that tested the effect of omega-3 fatty acids enriched nutrition on septic patients. And we limited citations to prospective randomized controlled trials in adults. The following search terms were used: 1) omega-3 fatty acids, fish oil, eicosapentaenoic acid, or docosahexaenoic acid; 2) sepsis, severe sepsis, or septic shock. In order to identify other potentially eligible studies that had not been captured with our primary electronic search, the reference lists of retrieved published papers and recent reviews were also reviewed. The literature language was restricted to English.

**Study selection**
Two investigators (WT and ZS) reviewed studies for inclusion, retrieved potentially relevant studies, and decided on study eligibility independently. Any differences were resolved by consensus. Agreements of trial eligibility between reviewers were assessed by using Cohen’s k [20]. As the current meta-analysis was based on trials which published previously, no ethical approval or patient consent was required.

**Inclusion criteria**
Studies were considered eligible if the following criteria were present: 1) the study design was a randomized controlled trial in adults (≥18 years of age); 2) subjects were patients with sepsis, severe sepsis, or septic shock [21]; 3) the study compared omega-3 fatty acids enriched nutrition (administered via either parenteral or enteral route) with control (septic patients treated with an omega-3 fatty acids deficiency nutrition); 4) the mortality (at 28-days or, if not available, mortality at any time was recorded), the length of ICU stay, the duration of hospital stay, infectious complications, or the duration of mechanical ventilation was reported.

**Exclusion criteria**
The exclusion criterion was: using healthy people as control, administration strategies were different between study and control group, the article was a review, editorial, children’s research, animal study, letter or other type of publication not based on original research, or the study did not include extractable outcomes.

**Data extraction and quality assessment**
The following items from the each study were extracted into standardized data abstraction forms by two reviewers (WT and ZS) independently: first author’s last name, publication year, sample size, country of origin, the composition of nutrition, administration strategies, and secondary organ dysfunction. The primary outcome was mortality. The secondary outcomes were the length of ICU stay, the duration of hospital stay, infectious complications, and the duration of mechanical ventilation. The methodological quality of each trial was evaluated by two of the researchers (WT and ZS) independently, and the Jadad’s scale and Cochrane Handbook for risks of bias assessments were used [22, 23].

**Statistical analysis**
RevMan software (version 5.3.5) was used in our meta-analysis. We reported binary outcomes as risk ratios (RR) and continuous outcomes as weighted mean differences (WMD). Summary effect estimates were presented with 95 % confidence interval (CI). Heterogeneity was explored for all the meta-analysis. Statistical heterogeneity was measured and quantified using the $I^2$ test and the Mantel–Haenszel $\chi^2$ test. Statistical heterogeneity was predefined at $I^2 > 50\%$ or $P < 0.05$ by Mantel–Haenszel $\chi^2$ test. We reported results from a fixed effect model if there was no statistical heterogeneity ($P \geq 0.05$ or $I^2 \leq 50\%$), or, a randomized effect model was used. Publication bias was assessed for all analysis after visual inspection of funnel plots. The Cohen’s k was used to assess the agreements between reviewers for trial eligibility and methodological quality assessment [20].

**Results**

**Search results**
256 potentially relevant articles were identified after an electronic searching from among 255 listed in the PubMed database, and one article after evaluating the reference lists of retrieved reviews. Most of the 256 articles were excluded for reasons such as studies of children, reviews, not relevant to our meta-analysis, or animal studies after screening titles and abstracts. Then, fourteen relevant trials were yielded [8–17, 24–27]. After a full-text assessment, three trials [24, 25, 27] were excluded for reasons such as using healthy people as control [24, 25], comparing enteral with parenteral nutrition of omega-3 fatty acids not control (septic patients treated with an omega-3 fatty acids deficiency nutrition) [27] (Fig. 1). Finally, we included eleven randomized controlled trials [8–17, 26] in the present meta-analysis which were completely agreed by two reviewers ($k = 1$). We excluded 8 trials that included in a previous meta-analysis [18] based on our inclusion and exclusion criteria (5 published in Chinese language, two using healthy...
people as control, one was published as abstracts). Our study included four trials [8, 12, 13, 17] investigated the effect of enteral omega-3 fatty acids nutrition on septic patients. And three new randomized controlled trials [9–11] investigate parenteral nutrition were included in the present meta-analysis. Figure 1 shows a flowchart of study selection at different stages of the meta-analysis.

Characteristics and the quality of studies
The included eleven trials were published from 2003 to 2015 and enrolled an aggregate of 808 patients, including 405 patients in the study group and 403 in the control group. We did not have access to primary data and therefore were reliant on the case definitions of sepsis used by the authors of the individual studies. The sizes of studies ranged from 25 to 198. Table 1 presents the characteristics of the 11 randomized controlled trials which were conducted in Europe, Brazil, or Asia. Most of the randomized controlled trials were single center, except two trials were multicentre studies [12, 13]. Additional file 1: Table S1 shows detailed information about the quality assessment of the included studies, including the Jadad score and the results of allocation concealment.

Effect of omega-3 fatty acids on mortality
Mortality was reported in ten studies, we combined these trials in the mortality analyses. A fixed effect model was used, as no heterogeneity was observed across the trials (I² = 0 %; Fig. 2). Our meta-analysis showed that omega-3 fatty acids did not reduce mortality (risk ratio 0.84; 95 % CI: 0.67 to 1.05, P = 0.12; Fig. 2). However, a publication bias may exist in the meta-

Table 1 Details of included trials

| Author          | Population                                      | Route of Administration | Details of administration | Mortality |
|-----------------|-------------------------------------------------|-------------------------|---------------------------|-----------|
| Shirai, 2015    | 1 center, 46 patients, sepsis-induced ARDS       | EN                      | Oxepa                     | Ensure Liquid | 60 days |
| Hall, 2015      | 1 center, 60 patients, sepsis                   | PN                      | Omegaven                  | standard medical care | 28 days |
| Burkart, 2014   | 1 center, 50 patients, sepsis                   | PN                      | Omegaven                  | standard treatment | Hospital |
| Gultekin, 2014  | 1 center, 58 patients, severe sepsis or septic shock | PN                      | Omegaven + ClinOleic      | ClinOleic    | Unspecified |
| Pontes-Arruda, 2011 | 5 centers, 115 patients, early stages of sepsis | EN                      | Oxepa                     | Ensure Plus HN | 28 days |
| Grau-Carmona, 2011 | 11 centers, 198 patients, septic patients with ALI or ARDS | EN                      | Oxepa                     | Ensure Plus HN | Unspecified |
| Khor, 2011      | 1 center, 28 patients, severe sepsis            | PN                      | Omegaven                  | normal saline | normal saline |
| Barbosa, 2010   | 1 center, 25 patients, sepsis or SIRS           | PN                      | Lipolus                   | NutRIflex Lipid Special | 28 days |
| Friesecke, 2008 | 1 center, 166 patients, critically ill patients (115 SIRS, 51 non-SIRS) | PN                      | Omegaven + Lipofundin     | Lipofundin   | 28 days |
| Pontes-Arruda, 2006 | 1 center, 165 patients, severe sepsis or septic shock | EN                      | EPA-GLA enriched diet     | Control Diet | 28 days |
| Grecu, 2003     | 1 center, 54 (15 in ICU) patients, abdominal sepsis | PN                      | Omegaven + LCT            | LCT         | ICU |

ARDS acute respiratory distress syndrome, ALI acute lung injury, SIRS Systemic inflammatory response syndrome, EN enteral nutrition, PN parenteral nutrition, LCT Long-chain triglycerides, EPA eicosapentaenoic acid, GLA gamma-linolenic acid, Ensure Liquid, Ensure Plus HN, omega-3 fatty acids deficiency nutrition for EN; Lipofundin, NutRIflex Lipid Special, ClinOleic, omega-3 fatty acids deficiency nutrition for PN; Oxepa, omega-3 fatty acids enriched nutrition for EN; Omegaven, omega-3 fatty acids enriched nutrition for PN
analysis that was focused on the mortality by the funnel plot analysis (Fig. 3).

**Effect of omega-3 fatty acids on infectious complications or the duration of mechanical ventilation**

Infectious complications were reported in five studies (Additional file 2: Table S2), we combined these trials in the meta-analysis. Our meta-analysis showed that omega-3 fatty acids did not affect infectious complications (risk ratio 0.95; 95 % CI: 0.72 to 1.25, \( P = 0.70 \); Fig. 4).

The duration of mechanical ventilation was reported in seven studies, but the data from five of them could be combined in the meta-analysis (Additional file 2: Table S2). Our meta-analysis showed that omega-3 fatty acids can reduce the duration of mechanical ventilation (WMD = −3.82; 95 % CI: −4.61 to −3.04; \( P < 0.00001 \); Fig. 5). However, a heterogeneity was found across the trials (\( I^2 = 40 \% \); Fig. 5). Sensitivity analyses suggested that no benefit on the duration of mechanical ventilation was observed among the remaining studies after excluded one study [8] (\( I^2 = 0 \% \); Additional file 3: Figure 5S). Thus, this result should be interpreted with caution.

**Effect of omega-3 fatty acids on the length of ICU or hospital stay**

Although 9 trials presented the length of ICU stay, the data from six of them could be analyzed in the meta-analysis (Additional file 4: Table S3). A marked heterogeneity was observed across the trial (\( I^2 = 87 \% \); Additional file 5: Figure 1S1). Additional file 5: Figure 1S1 shows the result from a randomized effect model that investigates the effect of omega-3 fatty acids on the length of ICU stay. According to our results, omega-3 fatty acids did not affect the length of ICU stay (WMD = −2.70; 95 % CI: −6.40 to 1.00, \( P = 0.15 \); Additional file 5: Figure 1S1). Sensitivity analyses were conducted to explore potential sources of heterogeneity. A mild heterogeneity was observed among the remaining studies (\( I^2 = 33 \% \); Additional file 6: Figure 1S2), after exclusion of two trial [8, 26]. But the exclusion of the trial [8, 26] did not materially alter the effect of omega-3 fatty acids on the length of ICU stay (Additional file 6: Figure 1S2).
We combined four trials in the length of hospital stay analysis. Our meta-analysis showed that omega-3 fatty acids did not affect the length of hospital stay (WMD = −2.82; 95 % CI: −9.88 to 4.23, P = 0.43; Additional file 7: Figure 2S1). A significantly heterogeneity was observed across the trial (I² = 93 %; Additional file 7: Figure 2S1).

Our sensitivity analyses suggested that after exclusion of one trial [26], no heterogeneity was observed among the remaining studies (I² = 0 %; Additional file 8: Figure 2S2). But the exclusion of the trial [26] did not materially alter the effect of omega-3 fatty acids on the length of hospital stay (WMD = 0.96; 95 % CI: −1.55 to 3.48, P = 0.45; Additional file 8: Figure 2S2).

Subgroup analysis
Subgroup analysis was performed to investigate that whether the effect of omega-3 fatty acids enriched nutrition on sepsis was influenced by its dose and composition, or a different administration route (either parenteral or enteral pathway). Our meta-analysis indicated that neither parenteral (risk ratio 0.84; 95 % CI: 0.61 to 1.14, P = 0.26; Additional file 9: Figure 3S1; included 6 trials) nor enteral (risk ratio 0.84; 95 % CI: 0.61 to 1.16, P = 0.29; Additional file 10: Figure 3S2; included 4 studies) omega-3 fatty acids nutrition influenced mortality in septic patients.

During the 11 trials included in the present meta-analysis, six trials investigated Omegaven (a commercially available omega-3 fatty acids enriched parenteral nutrition), however, only five of them reported mortality (risk ratio 0.84; 95 % CI: 0.61 to 1.16, P = 0.30; Additional file 11: Figure 4S1); Oxepa (a commercially available omega-3 fatty acids enriched enteral nutrition) was studied in three trials (risk ratio 1.03; 95 % CI: 0.66 to 1.62, P = 0.89; Additional file 12: Figure 4S2), one studies investigated self-made omega-3 fatty acids enriched enteral nutrition (risk ratio 0.63; 95 % CI: 0.39 to 1.00; Fig. 2) as well as one trial investigated Lipolus (a commercially available omega-3 fatty acids enriched parenteral nutrition, risk ratio 0.77; 95 % CI: 0.25 to 2.34; Fig. 2). Our meta-analysis suggested that none of the four type of omega-3 fatty acids enriched nutrition has a benefit on mortality.

Discussion
The primary outcome of our meta-analysis suggested that omega-3 fatty acids nutrition has no benefit on reduction of mortality in septic patient. The secondary outcomes suggested that omega-3 fatty acids nutrition did not increase the infectious complications. Nevertheless, omega-3 fatty acids nutrition failed to show a beneficial effect on the length of hospital stay, or intensive care stay. However, the duration of mechanical ventilation was markedly reduced by omega-3 fatty acids.

A previous systematic review and meta-analysis of parenteral omega-3 fatty acids for sepsis found a beneficial effect on mortality (risk ratio 0.77; 95 % CI: 0.59 to 0.99, P = 0.04; 12 trials, 721 patients). Our study is not consistent with this work. The difference of enrolled trials
may attribute to the inconsistent result between our study and the previous meta-analysis. In the present meta-analysis, we also investigated whether the effect of omega-3 fatty acids on sepsis was different when it was administrated via parenteral or enteral pathway, and whether the dose and composition of omega-3 fatty acids nutrition could influence its effect.

Secondary organ dysfunction is a key factor that triggered death in septic patients [1, 3–5]. It has been found that omega-3 fatty acids nutrition may prevent new organ dysfunction in three randomized controlled trials with 278 cases of sepsis [9, 12, 17] (two trials investigated mild or early sepsis [9, 12], one study with severe sepsis or septic shock [17]). Thus, it seems that the omega-3 fatty acids may play a benefit on sepsis through inhibit new organ dysfunction. SOFA scores, an indicator of secondary organ dysfunction, were reported in three trials [8, 9, 13]. As it was unable to obtain explicit data on SOFA scores that could be combined in the meta-analysis, we did not analyze the effect of omega-3 fatty acids on SOFA scores. It seems that omega-3 fatty acids may have potential benefit on new organ dysfunction; we suggested that a further study focus on the effect of omega-3 fatty acids on sepsis should investigate secondary organ dysfunction. Mechanical ventilation is a lifesaving strategy for critical ill patients. However, its adverse effects such as ventilation-induced lung injury, and ventilator associated pneumonia are life threatening. Our meta-analysis included 5 trials (Fig. 5) suggested that omega-3 fatty acids can reduce the duration of mechanical ventilation in septic patient. This result is not consistent with a previous meta-analysis [18] which included two studies [15, 16]. Nevertheless, heterogeneity was found across the trials. Thus, the result should be interpreted with caution.

The potential mechanism that could possibly explain why omega-3 fatty acids may not be beneficial in septic patients was as follows: Firstly, sepsis is a severe disease with a high mortality [1, 3–5]. A number of factors such as a history of severe diseases, or divergence of pathogen may influence the clinic outcome. Septic patients often complicated with organ dysfunction or shock which may further elevate mortality. The included trials in our meta-analysis suggested that a number of patients diagnosed as sepsis were complicated organ dysfunction or shock. Acute respiratory distress syndrome, an inflammation disease with mortality over 40 %, is a common secondary organ dysfunction in septic patients [1, 3–5, 28]. A previous meta-analysis focused on the effect of omega-3 fatty acids on acute respiratory distress syndrome (ARDS) reported that it has no effect on reduction of 28-day mortality [29]. The failure on the improvement of complications by omega-3 fatty acids seems to have limited impact on septic patients’ survival.

Secondly, the rational of omega-3 fatty acids nutrition as an adjunctive therapy for sepsis is partly based on its anti-inflammatory and immunomodulating features. However, the mild anti-inflammatory effect of omega-3 fatty acids might not lead to improve in outcome. It has been reported that even a delay of antibiotics treatment may cause a significant increased mortality in patients with sepsis [30].

A previous meta-analysis [29] suggested that a high fat formula used in control group which may contribute to an increased mortality could be the reason that a reduced mortality was observed in study group. It is suggested that the high fat formula may have pro-inflammatory features, and resulting in a worsened clinical outcome [31]. It seems that clinical outcomes could be influenced by the dose and composition of nutrition. As the dose and composition of omega-3 fatty acids nutrition agent were divergent in studies, we are interested in that whether the effect of omega-3 fatty acids on sepsis may be affected by the difference of dose and composition. Therefore, we examined trials testing different type of omega-3 fatty acids agent separately. Our subgroup meta-analysis indicated that the effect of omega-3 fatty acids on mortality in septic patients was not influenced by its dose and composition.

We are also interested in that whether the difference between parenteral and enteral administration may influence the effect of omega-3 fatty acids on septic patients. In a previous meta-analysis [32] included three trials that reported a protective effect of omega-3 fatty acids on ARDS, the administration strategy was enteral nutrition. Our subgroup meta-analysis suggested that the mortality in septic patients was not influenced by omega-3 fatty acids administrated through either parenteral or enteral pathway. This result is consistent with a previous meta-analysis that focuses on the effect of omega-3 fatty acids on critically ill patients [33]. These results suggested that the administration strategy may not be the key factor that influenced the effect of omega-3 fatty acids on sepsis or other critically ill patients.

There are some limitations in our meta-analysis. One potential limitation of the present meta-analysis was the asymmetric funnel plot that suggested publication bias may exist. It is possibly that the present meta-analysis did not include all of the trials, as we restricted the literature language to English, and other database except the PubMed was not adopted. Meanwhile, the small sample size may also have been a limitation, which may have lowered the statistical power. Furthermore, a marked heterogeneity was detected when the length of ICU or hospital stay was analyzed.

In brief, although our meta-analysis suggested that omega-3 fatty acids failed to reduce overall mortality in
septic patients, a tendency toward a reduction in mortality should not be neglected (risk ratio 0.84; 95 % CI: 0.67 to 1.05, \( P = 0.12 \)). Thus, future large scale, multicentre investigation is still required to draw a conclusion.

Conclusions

Omega-3 fatty acids confer no mortality benefit but are associated with a reduction in mechanical ventilation duration in septic patients. However, low sample size and heterogeneity of the cohorts included in this analysis limits the generalizability of our findings.

Additional files

| Additional file | Description |
|----------------|-------------|
| Additional file 1: Table S1 | Jadad scores and methodology quality. (DOC 12 kb) |
| Additional file 2: Table S2 | Details of omega-3 fatty acids nutrition on mechanical ventilation days or infectious complications in septic patients. (DOC 14 kb) |
| Additional file 3: Figure S5 | Sensitivity analyses the effect of omega-3 fatty acids on the duration of mechanical ventilation in septic patients. (TIF 22 kb) |
| Additional file 4: Table S3 | Details of Omega-3 fatty acids nutrition on new organ dysfunction, or the length of ICU or hospital stay. (DOC 18 kb) |
| Additional file 5: Figure S15 | Forest plots show the effect of omega-3 fatty acids on the length of ICU stay in septic patients. (TIF 25 kb) |
| Additional file 6: Figure S152 | Sensitivity analyses the effect of omega-3 fatty acids on the length of ICU stay in septic patients. (TIF 22 kb) |
| Additional file 7: Figure S251 | Forest plots show the effect of omega-3 fatty acids on the length of hospital stay in septic patients. (TIF 14 kb) |
| Additional file 8: Figure S252 | Sensitivity analyses the effect of omega-3 fatty acids on the length of hospital stay in septic patients. (TIF 12 kb) |
| Additional file 9: Figure S351 | Forest plots show the effect of parenteral omega-3 fatty acids nutrition on mortality in septic patients. (TIF 15 kb) |
| Additional file 10: Figure S352 | Forest plots show the effect of enteral omega-3 fatty acids nutrition on mortality in septic patients. (TIF 14 kb) |
| Additional file 11: Figure S451 | Forest plots show the effect of omegaven on mortality in septic patients. (TIF 15 kb) |
| Additional file 12: Figure S452 | Forest plots show the effect of Oxepa on mortality in septic patients. (TIF 13 kb) |

Abbreviations

ARDS, acute respiratory distress syndrome; CI, confidence interval; ICU, intensive care unit; PRISMA, The Preferred Reporting Items for Systematic reviews and Meta Analysis; RR, risk ratios; SOFA, sequential organ failure assessment; WMD, weighted mean differences.

Acknowledgements

We thank Hong-Mei Du for helping collecting data and Dr. Xiang-Ming Li for assistance with the meta-analysis.

Funding

None.

Availability of data and materials

All the data supporting these findings is contained within this manuscript.

Authors’ contributions

WT and PSL conceived and designed the study, analyzed and interpreted data. WT acquired data and drafted the manuscript. ZS acquired and interpreted data, and revised the manuscript. SL conceived and designed the study. YSS revised the manuscript. The final manuscript was reviewed and approved by all authors.

Competing interests

We declare that there have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This is not applicable as it’s a meta-analysis.

Author details

1Department of Burns and Plastic Surgery, Subei People’s Hospital of Jiangsu province, Jiangsu 225001, People’s Republic of China. 2Department of Outpatient, Subei People’s Hospital of Jiangsu province, Jiangsu 225001, People’s Republic of China. 3Department of Thoracic Surgery, Subei People’s Hospital of Jiangsu province, Jiangsu 225001, People’s Republic of China.

Received: 12 October 2015 Accepted: 1 June 2016

Published online: 18 July 2016

References

1. Rochaud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ. 2003;326:262–6.
2. Xiu F, Jeschke MG. Perturbed mononuclear phagocyte system in severely burned and septic patients. Shock. 2013;40:81–8.
3. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365:63–78.
4. Mark PE. Early management of severe sepsis: concepts and controversies. Chest. 2014;145:1407–18.
5. Stevenson EK, Rubinstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. Crit Care Med. 2014;42:625–31.
6. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.
7. Calder PC. Polysaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie. 2009;91:791–5.
8. Shirai K, Yoshida S, Matsumaru N, Toyoda I, Ogura S. Effect of enteral diet enriched with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with sepsis-induced acute respiratory distress syndrome. J Intensive Care. 2015;3:24.
9. Hall TC, Bilku DK, Al-Leswas D, Neal CP, Horst C, Cooke J, Metcalfe MS, Dennison AR. A randomized controlled trial investigating the effects of parenteral fish oil on survival outcomes in critically ill patients with sepsis: a pilot study. JPEN J Parenter Enteral Nutr. 2015;39:301–12.
10. Burkhardt CS, Dell-Kuster S, Siegemund M, Pargger H, Marsch S, Strebel SP, Steiner LA. Effect of n-3 fatty acids on markers of brain injury and incidence of sepsis-associated delirium in septic patients. Acta Anaesthesiol Scand. 2014;58:689–700.
11. Gultekin G, Sahin H, Inanc N, Uyanik F, OK E. Impact of Omega-3 and Omega-9 fatty acids enriched total parenteral nutrition on blood chemistry and inflammatory markers in septic patients. Pak J Med Sci. 2014;30:299–304.
12. Pontes-Amuda A, Martins LF, de Lima SM, Isola AM, Toledo D, Roende E, Maia M, Magnan GB, Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group. Enteral nutrition with eicosapentaenoic acid, \( \gamma \)-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study. Crit Care. 2011;15:R144.
13. Grau-Carmona T, Morán-García V, García-de-Lorenzo A, Heras-de-la-Calle G, González JC, Blesa-Malpica A, Albert-Bonamusa I, Bonet-Saris A, Herrero-Meseguer JJ, Mesejo A, Acosta J. Effect of an enteral diet enriched with eicosapentaenoic acid, gamma-linolenic acid, and anti-oxidants on the length of ICU stay in septic patients. J Intensive Care. 2015;3:24.
14. Steiner LA. Effect of n-3 fatty acids on markers of brain injury and incidence of sepsis-associated delirium in septic patients. Acta Anaesthesiol Scand. 2014;58:689–700.
15. Barbosa VM, Miles EA, Calhau C, Lafuente E, Calder PC. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory...
markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Crit Care. 2010;14:R5.

16. Friesecke S, Lotze C, Köhler J, Heinrich A, Felix SB, Abel P. Fish oil supplementation in the parenteral nutrition of critically ill medical patients: a randomised controlled trial. Intensive Care Med. 2008;34:1411–20.

17. Pontes-Arruda A, Araújo AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34:2325–33.

18. Mo Y, Hu X, Chang L, Ma P. The effect of ω-3 fatty acid supplementation in parenteral nutrition on the outcome of patients with sepsis: a systematic review and meta-analysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26:142–7.

19. Liberatori A, Altman DG, Tetzlaff J, Mulrow C, Ioannidis JP, Clarke M, Devereaux PJ, Kéblin J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.

20. Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33:613–9.

21. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–6.

22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

23. Zhao JG. Identifying and measuring heterogeneity across the studies in meta-analysis. J Hand Surg Am. 2013;38:1449–50.

24. Mayer K, Fegbeutel C, Hattar K, Sibelius U, Krämer HJ, Heuer KU, Temmesfeld-Wollbrück B, Gokorsch S, Grimmeringer F, Seeger W. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med. 2003;29:1472–81.

25. Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, Seeger W, Grimmeringer F. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med. 2003;167:1321–8.

26. Grecu I, Mirea L, Grintescu I. Parenteral fish oil supplementation in patients with abdominal sepsis. Clin Nutr. 2003;22:523.

27. Bertolini G, Iapichino G, Radrizzani D, Facchini R, Simini B, Bruzzone P, Zanforlin G, Tognoni G. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med. 2003;29:834–40.

28. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008;133:1120–7.

29. Zhu D, Zhang Y, Li S, Gan L, Feng H, Nie W. Enteral omega-3 fatty acid supplementation in adult patients with acute respiratory distress syndrome: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40:504–12.

30. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Supples R, Feinstein D, Zanotti S, Talberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.

31. Manzanares W, Dhaliviwal R, Jurewitsch B, Stapleton RD, Krejeebhow KN, Heyland DK. Alternative lipid emulsions in the critically ill: a systematic review of the evidence. Intensive Care Med. 2013;39:183–94.

32. Pontes-Arruda A, Demichele S, Seth A, Singer P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a metaanalysis of outcome data. JPN J Parenter Enteral Nutr. 2008;32:596–605.

33. Manzanares W, Langlois PL, Dhaliviwal R, Lemieux M, Heyland DK. Intravenous fish oil lipid emulsions in critically ill patients: an updated systematic review and meta-analysis. Crit Care. 2015;19:167.